Get Involved in Diabetes Research
Looking to make a difference in the world of type 1 diabetes? Consider signing up for a clinical trial! Getting involved in studies helps improve diabetes care for all. Some studies are simply online surveys, where others are testing out new diabetes devices or medications.
Listed below are studies that are currently recruiting participants, with links where you can contact the study coordinator or center. You can also check out clinicaltrials.gov and search for “type 1 diabetes” to find all active clinical trials in the U.S.
- NEW: If you are a young person living 14- 25 years with diabetes or a parent/caregiver, please have your say on the International Joint Diabetes Transition Services Survey- an initiative by ISPAD, ADA, and EASD. Take the survey here.
- NEW: Are you a young adult who attends/attended college and/or university between the ages of 18-25 with T1D? If you answer yes to all 3 of these questions, then we want to recruit you to learn more about your perceptions as a young adult who is managing type 1 diabetes on a college/university campus. View the pdf to learn more.
NEW: TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people (ages 12-35) newly diagnosed with type 1 diabetes (Stage 3 T1D). To learn more and sign up for the JAK Inhibitors Newly Diagnosed Study, visit: trialnet.org/jakpot.
NEW: The Designate Study aims to see how the experimental study drug, siplizumab, can block or weaken the cells that attack beta cells in the pancreas. This would allow the beta cells to continue to function and produce insulin. The study is for those 18 - 45 years of age, diagnosed with T1D in the last 18 months. Compensation is provided. If interested contact Hali at 303-724-7526 or check out: www.designate-study.org.
NEW: Indiana University is studying a drug known as difluoromethylornithine (DFMO) that may reduce stress in cells that make insulin and preserve your body’s own insulin production. To learn more and to see if you qualify, click here.
- NEW: Dr. Laura Cudizio, CWD-JENIOUS award recipient from 2023, is conducting a study assess the experience of families with children and adolescents with type 1 diabetes and their care during the school period. The survey is being conducted worldwide in multiple languages to identify barriers and determine needs to improve diabetes care in school globally. The survey in English.
- NEW: Survey on Sex Differences in Glucose Control and Diabetes Management hopes to highlight the differences between female and male in diabetes management and gather evidence on extra difficulties that females may experience related to menstrual cycle and menopause. Males are also encouraged to complete the survey which should take about 10 minutes to complete.
- NEW: Are you an adult 60 years or older with Type 1 Diabetes who uses a CGM? University of Utah College of Nursing is conducting a study for adults and their partners who are able to view CGM data on their phone. If you're interested please contact Bruno Gonzalez [email protected]
- NEW: If you have a child aged 2 - 5 years with Type 1 diabetes who is not on an insulin pump, they may be eligible for a new study. This study will explore how Artificial Intelligence (AI) can help doctors choose pump settings in a system that uses automated insulin delivery. The study is sponsored by NIH. For more information go to: www.jaeb.org/pedapai
NEW: The ATG Prevention Study (STOP-T1D) study is testing a low dose of the immunotherapy drug anti-thymocyte globulin (ATG) to see if it can delay or prevent type 1 diabetes (T1D) in people ages 12 to 34 who have a 50% risk of clinical diagnosis within 2 years. Risk is defined by having two or more autoantibodies and abnormal blood sugar, plus at least one high-risk marker (based on test results). In a previous TrialNet study for people newly diagnosed with T1D, low-dose ATG preserved insulin production and improved blood sugar control for 2 years. Learn more and enroll here.
NEW: The T1D RELAY This study is testing rituximab-pvvr and abatacept in people (ages 8-45) who were newly diagnosed with type 1 diabetes (T1D) to learn if using both immune therapies, one after the other, maintains the body’s ability to make insulin. By adding abatacept after rituximab-pvvr, researchers predict more people will experience prolonged beta cell function during and possibly after treatment. Learn more and enroll here.
An international research team would like to determine the perceptions of adolescents, young adults, their adult carers, and healthcare professionals around the transition from paediatric to adult diabetes healthcare services. We intend to use study findings to help formulate international consensus guidelines on transition between paediatric and adult-based diabetes healthcare services (by the International Society for Pediatric and Adolescent Diabetes, the American Diabetes Association, and the European Association for the Study of Diabetes). As a person with diabetes (or adult carer), we invite you to participate in an online survey, which will take around 15 minutes to complete. Learn more.
TrialNet researchers are testing low-dose anti-thymocyte globulin (ATG), an immunotherapy, to find out if it can delay or prevent type 1 diabetes (T1D) in people at high risk of clinical diagnosis (Stage 3) within two years. Learn more.
- Researchers at University of South Florida are conducting a study about Mindfulness for Adolescents with Type 1 Diabetes. The study is for people with type 1 diabetes for more than 6 months between the ages of 12-19 years old. For more information, reach out to the study coordinator, Nicole Rios at [email protected].
- The Stanford University Diabetes Body Acceptance Program is investigating two programs designed to improve body acceptance and your relationship with food. If you are an individual between the ages of 14-35 with Type 1 Diabetes then you may be eligible to participate. You could earn up to $110. All activities are completely virtual - Fill out this form to learn more.
- Researchers at Texas Children's Hospital are looking for Teenagers with diabetes aged 14-17 to make videos that empower younger children living with type 1 diabetes. They encourage you to get creative and have fun with this project! Sign up link here.
- Stanford University is recruiting for the Happy T1D Study for people with type 1 diabetes between ages 14-25 years and involves meeting with someone about topics such as diabetes distress and glucose monitoring via zoom. There are also online surveys and other data collection. For more information, fill out the survey here.
- The National Institute of Diabetes and Digestive Kidney Diseases is sponsoring a pilot study in people with T1DM who are over 60 years old and use a CGM device. Learn more here.
- Coin 2 dose is a study for Teenagers with diabetes between the ages of 11-17 years old who have had T1D for at least 6 months. The study is looking to help improve bolusing in teenagers. For more information, there is a video at this link.
- Research study that aims to evaluate the safety and effectiveness of a mealtime insulin that is inhaled in children and teenagers ages 4-17 with Type 1 or Type 2 diabetes. The study involves clinic visits, blood draws, and lung function tests. Qualified participants will join one of two groups. The first group will take inhaled insulin for 12 months. The second group will continue mealtime injectable insulin for 6 months and then switch to inhaled insulin for 6 months. For more information on INHALE-1 study, click here or contact [email protected].
- Stanford University is looking for people with diabetes who have been hospitalized or gone to an emergency department in the last year. They have a survey about experiences with diabetes technology in the hospital setting.
- Clinical for teplizumab (TZield) in children less than 8 years old who are in stage 2 of type 1 diabetes is actively recruiting. There are multiple study sites The link to the study can be found here.
- Study for adults with T1D ages 18-45 seeing if a new medically designed probiotic will improve beta cell function, gastrointestinal health, immune function, and c-peptide levels in study participants. The study is at the University of Florida Campus in Gainesville, Florida and involves 4 in-person visits over a year. Must be willing to consume study probiotic capsule daily for 24 weeks. Contact Miriam Cintron, study coordinator, [email protected] for more information.
- Skylight Health Research is enrolling patients (aged 4-30) with Type 1 and Type 2 Diabetes into a post-market study evaluating Abbott's continuous glucose monitor, the Freestyle Libre 2. Eligible participants will be provided with the Libre at no cost to them for 6 months and will be compensated for their time and efforts participating in the study. Participants will be able to share their readings with their providers if they choose. For questions, email Alisha: [email protected]
- Researchers at the University of Texas are looking for Young Adults between the ages of 18-25 with Diabetes or other qualifying health conditions to participate in a research study investigating what influences readiness to transition to adult care. This will be a one-time online survey. For more information please contact at this email: [email protected] or this phone number: 512-593-2360.
- Survey for parents of children with chronic health conditions at Baylor University. Parent and siblings participate in zoom sessions and complete questionnaires. For more information and interest to participate, please contact: Tatum Zeleznik at [email protected]
- Survey on awareness and behaviors associated with alcohol consumption among people with type 1 diabetes - This questionnaire is aimed at people with type 1 diabetes ages 16-35 years old. Its main purpose is to identify patterns of behavior associated with alcohol consumption. The questionnaire can be found here: t1drink.umed.pl/en.
- A 2nd year PhD student at Rosalind Franklin University of Medicine and Science is conducting a study that seeks to understand more about the relationships young adults (age 18-29) with type 1 diabetes have with their medical providers, and how these relationships impact their diabetes management. If you are between the ages of 18-29, have type 1 diabetes, have seen your endocrinologist in the last year, and can read English please consider participating! Learn more about the study and take the survey.
- Wayne State University’s Department of Family Medicine is offering a mobile health (mHealth) study for young adults ages 16-25 years old diagnosed with type 1 diabetes (T1D). This study aims to see if T1D management and health outcomes are improved by using cellphones. Click here to learn more and to see if you are eligible. Please contact the research team at [email protected] or 313-731-2814 for more information.
- Are you the parent of an emerging adult (aged 15-25) with type 1 diabetes? The purpose of this study is to identify desired types and mechanisms of support for parents during their emerging adult’s transition to adulthood with T1D. Click here to access the confidential online screening questionnaire. Participants who complete both the survey and the focus group will be entered into a drawing to win a $100 Amazon.com e-gift card!
- Join a Dartmouth College study and get an app that may help you manage your diabetes! Inviting young adults aged 19-29 years old who are diagnosed with type 1 diabetes for 18 months or more. Participants will be compensated for participating. Click here to learn more and complete the eligibility survey!
- Market Research Study: The purpose of this research is to evaluate the messages and information that will be included in educational materials being developed for the T1D community. Research will be conducted through a 60-minute web-assisted one-on-one interview, and selected participants will be compensated for their time. If you or one of your family members have been screened and tested positive for 2 or more T1D-related autoantibodies, please consider filling out this form.
- The purpose of the VX-880 Islet Cell Infusion study sponsored by Vertex Pharmaceuticals is to evaluate the safety, tolerability, and effectiveness of an investigational islet cell infusion called VX-880. The goal of this infusion is to provide replacement cells for the ones that have been lost or don’t work properly in people with diabetes. Participants may be compensated financially for study-related time and reimbursed for travel. Learn more and see if you qualify.
- The Gladiator Study was designed to further evaluate whether ladarixin is effective in preserving β-cell function and slowing down the progression of T1D in patients with a more severe disease presentation. This study is for patients diagnosed with T1D within 100 days from first insulin administration who are 14-45 years old. Learn more. For questions, contact Hali Broncucia at [email protected].
- The MAS-1 Study is working to prove that MAS-1 vaccine is safe and promotes anti-inflammatory pathways while decreasing auto-inflammatory actions in the body. This study is looking for patients diagnosed with T1D within previous 2 years who are 18-45 years old. Learn more. For questions, contact Hali Broncucia at [email protected].
- Join the ATTEMPT study at SickKids! Teens ages 12 - 18 years with type 1 #diabetes (T1D) could receive a new oral medication taken with insulin to see if it helps prevent complications and improve glycemic control. This study is being conducted in Ontario, Canada. To participate, reach out to [email protected].
- The Overcoming Barriers and Obstacles to Adopting Diabetes Devices (ONBOARD) study is seeking participants for our research study about barriers to uptake of continuous glucose monitoring (CGM) in adults with type 1 diabetes. Learn more here.
- Little is known about how families manage diabetes when multiple family members have type 1 diabetes. Such families may have strategies they share that make living with T1D easier. The University of Utah is conducting a multi T1 study - get more information here!